News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Valuable new resource could speed up the development of new drugs targeting cell cycle disruptions
Using an innovative scientific approach, scientists have obtained a wealth of new data on many of the proteins responsible for regulating the cell cycle – a sequence of molecular events that culminates in the production of two daughter cells.
ICR welcomes approval for new ovarian cancer drug combination
The Institute of Cancer Research, London, has welcomed the approval of a new combination of two drugs for ovarian cancer by the US regulatory body the Food and Drug Administration (FDA).
New weakness to target breast cancer cells discovered
Researchers at The Institute of Cancer Research, London, have uncovered a hidden weakness in some breast cancer tumours that could lead to smarter treatment decisions.
945x532.png?sfvrsn=310c2acf_2 "Cell Division-(green-4-3)945x532")
New protective role of gene frequently mutated in cancer uncovers potential therapeutic target
New research into how cancer develops has uncovered more detail about the importance of the centromere, a region of human DNA that has a critical role in effective cell division.
-mucinous-ovarian-tumour---945x532.jpg?sfvrsn=5e9bb32b_2 "Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour - 945x532")
Smarter chemotherapy approach could delay drug resistance in ovarian cancer
Adaptive chemotherapy – a personalised approach to giving chemotherapy – can prolong survival in lab models of ovarian cancer, according to new results published in the journal Cancer Research.
ICR welcomes plans for £1 billion development to create world-leading cancer research district in Sutton
The Institute of Cancer Research has welcomed new plans to deliver around one million square feet of state-of-the-art research and laboratory space for life-sciences companies in Sutton, south London, where they will be located next door to our researchers.
New study uncovers precise mechanism by which telomeres help prevent cancer-driving genetic changes
Scientists have worked out how a protective element of our DNA helps prevent an abnormal genetic event that can lead to cells becoming cancerous.
-being-attacked-by-two-cytotoxic-t-cells-(red)-547x410.tmb-hbmobile.png?Culture=en&sfvrsn=8f59440b_2 "Immunotherapy - Oral squamous cancer cell (white) being attacked by two cytotoxic T cells (red) 547x410")
Immunotherapy gives head and neck cancer patients extra years disease free
An immunotherapy treatment helps patients live years longer without their cancer getting worse or coming back, a major phase III trial has found.
Molecular profiling is key to better outcomes for young adults with brain cancer, study shows
A recent study on an aggressive type of brain cancer has significantly advanced the understanding of the spectrum of tumours that occur in teenagers and young adults (TYA).
).jpg?sfvrsn=83bdab30_1 "DNA Genotyping and Sequencing (National Cancer Institute (NCI))")
Genetic study links common form of testicular cancer to rare variants in cell structure genes
The largest study to date of most common form of testicular cancer has uncovered a possible link between disease risk and variations in the genes controlling cell shape and movement.
Overuse of CT scans could cause 100,000 extra cancers in US
The overuse of CT scans could cause over 100,000 cases of cancer in the US – with almost 10,000 cases in children, researchers have warned.
ICR welcomes NICE recommendation of capivasertib for advanced breast cancer
The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most common type of advanced breast cancer with specific biomarker alterations (PIK3CA, AKT1 or PTEN).
